Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial

Abstract Background Pathogenesis in non-alcoholic steatohepatitis (NASH) involves abnormal cholesterol metabolism and hepatic accumulation of toxic free cholesterol. Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Renger G. Tiessen, Ciara A. Kennedy, Bradley T. Keller, Nancy Levin, Lisette Acevedo, Bronislava Gedulin, Andre A. van Vliet, Alejandro Dorenbaum, Melissa Palmer
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2018-01-01
coleção:	BMC Gastroenterology
Assuntos:	Apical sodium-dependent bile acid transporter Bile acids Clinical pharmacology Non-alcoholic steatohepatitis Non-alcoholic fatty liver disease Phase 1 clinical trial
Acesso em linha:	http://link.springer.com/article/10.1186/s12876-017-0736-0
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!